Swedish Orphan Biovitrum AB (publ) to Acquire Dova Pharmaceuticals Creating a Global Growth Platform in Haematology Call Transcript
Ladies and gentlemen, welcome to the Sobi to acquire Dova Pharmaceuticals, creating a global growth platform in hematology webcast.
I will now hand over to Guido Oelkers, CEO. Please go ahead.
()-&
Yes. Good morning, and thank you. Good morning, everybody, and thanks for your early attention to our story. And what I would like to share with you today is really the source behind the Dova acquisition -- Dova Pharmaceutical acquisition and also share -- shed some light on the other announcement that we have made recently with regard to the early opt-in regarding BIVV001.
So maybe with this, let's go right into the action. I will be joined during this call by our Chief Financial Officer, Henrik Stenqvist; and our Chief Medical Officer, Milan Zdravkovic.
With this having said, so basically what is Dova and/or Doptelet? Dova is a single asset company and Doptelet being the main asset is an orally administered TPO. We think it's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
